Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress

Overloaded glucose levels in several metabolic diseases such as type 2 diabetes (T2D) can lead to mitochondrial dysfunction and enhanced production of reactive oxygen species (ROS). Oxidative stress and altered mitochondrial homeostasis, particularly in the cardiovascular system, contribute to the d...

ver descrição completa

Detalhes bibliográficos
Autores: Luna-Marco, C, Iannantuoni, F, Hermo-Argibay, A, Devos, D, Salazar, JD, Víctor, VM, Rovira-Llopis, S
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p19596
Acesso em linha:https://incliva.portalinvestigacion.com/publicaciones/19596
Access Level:acceso abierto
Palavra-chave:Diabetes
SGLT2 inhibitors
GLP-1 receptor agonists
Heart disease
Mitochondria
Oxidative stress
ROS
Obesity
Inflammation
id ES_8ee895c8a2984174cfcffc7bb4081242
oai_identifier_str oai:incliva.fundanetsuite.com:p19596
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stressLuna-Marco, CIannantuoni, FHermo-Argibay, ADevos, DSalazar, JDVíctor, VMRovira-Llopis, SDiabetesSGLT2 inhibitorsGLP-1 receptor agonistsHeart diseaseMitochondriaOxidative stressROSObesityInflammationOverloaded glucose levels in several metabolic diseases such as type 2 diabetes (T2D) can lead to mitochondrial dysfunction and enhanced production of reactive oxygen species (ROS). Oxidative stress and altered mitochondrial homeostasis, particularly in the cardiovascular system, contribute to the development of chronic comorbidities of diabetes. Diabetes -associated hyperglycemia and dyslipidemia can directly damage vascular vessels and lead to coronary artery disease or stroke, and indirectly damage other organs and lead to kidney dysfunction, known as diabetic nephropathy. The new diabetes treatments include Na+-glucose cotransporter 2 inhibitors (iSGLT2) and glucagon-like 1 peptide receptor agonists (GLP-1RA), among others. The iSGLT2 are oral anti -diabetic drugs, whereas GLP-1RA are preferably administered through subcutaneous injection, even though GLP-1RA oral formulations have recently become available. Both therapies are known to improve both carbohydrate and lipid metabolism, as well as to improve cardiovascular and cardiorenal outcomes in diabetic patients. In this review, we present an overview of current knowledge on the relationship between oxidative stress, mitochondrial dysfunction, and cardiovascular therapeutic benefits of iSGLT2 and GLP-1RA. We explore the benefits, limits and common features of the treatments and remark how both are an interesting target in the prevention of obesity, T2D and cardiovascular diseases, and emphasize the lack of a complete understanding of the underlying mechanism of action.ELSEVIER SCIENCE INC2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/19596FREE RADICAL BIOLOGY AND MEDICINEISSN: 08915849ISSNe: 18734596reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p195962026-06-07T16:35:31Z
dc.title.none.fl_str_mv Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
title Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
spellingShingle Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Luna-Marco, C
Diabetes
SGLT2 inhibitors
GLP-1 receptor agonists
Heart disease
Mitochondria
Oxidative stress
ROS
Obesity
Inflammation
title_short Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
title_full Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
title_fullStr Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
title_full_unstemmed Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
title_sort Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
dc.creator.none.fl_str_mv Luna-Marco, C
Iannantuoni, F
Hermo-Argibay, A
Devos, D
Salazar, JD
Víctor, VM
Rovira-Llopis, S
author Luna-Marco, C
author_facet Luna-Marco, C
Iannantuoni, F
Hermo-Argibay, A
Devos, D
Salazar, JD
Víctor, VM
Rovira-Llopis, S
author_role author
author2 Iannantuoni, F
Hermo-Argibay, A
Devos, D
Salazar, JD
Víctor, VM
Rovira-Llopis, S
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Diabetes
SGLT2 inhibitors
GLP-1 receptor agonists
Heart disease
Mitochondria
Oxidative stress
ROS
Obesity
Inflammation
topic Diabetes
SGLT2 inhibitors
GLP-1 receptor agonists
Heart disease
Mitochondria
Oxidative stress
ROS
Obesity
Inflammation
description Overloaded glucose levels in several metabolic diseases such as type 2 diabetes (T2D) can lead to mitochondrial dysfunction and enhanced production of reactive oxygen species (ROS). Oxidative stress and altered mitochondrial homeostasis, particularly in the cardiovascular system, contribute to the development of chronic comorbidities of diabetes. Diabetes -associated hyperglycemia and dyslipidemia can directly damage vascular vessels and lead to coronary artery disease or stroke, and indirectly damage other organs and lead to kidney dysfunction, known as diabetic nephropathy. The new diabetes treatments include Na+-glucose cotransporter 2 inhibitors (iSGLT2) and glucagon-like 1 peptide receptor agonists (GLP-1RA), among others. The iSGLT2 are oral anti -diabetic drugs, whereas GLP-1RA are preferably administered through subcutaneous injection, even though GLP-1RA oral formulations have recently become available. Both therapies are known to improve both carbohydrate and lipid metabolism, as well as to improve cardiovascular and cardiorenal outcomes in diabetic patients. In this review, we present an overview of current knowledge on the relationship between oxidative stress, mitochondrial dysfunction, and cardiovascular therapeutic benefits of iSGLT2 and GLP-1RA. We explore the benefits, limits and common features of the treatments and remark how both are an interesting target in the prevention of obesity, T2D and cardiovascular diseases, and emphasize the lack of a complete understanding of the underlying mechanism of action.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/19596
url https://incliva.portalinvestigacion.com/publicaciones/19596
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCIENCE INC
publisher.none.fl_str_mv ELSEVIER SCIENCE INC
dc.source.none.fl_str_mv FREE RADICAL BIOLOGY AND MEDICINE
ISSN: 08915849
ISSNe: 18734596
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413168144449536
score 15,811543

Registos relacionados